Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.23B P/E - EPS this Y -33.30% Ern Qtrly Grth -
Income -105.37M Forward P/E -12.57 EPS next Y 20.50% 50D Avg Chg 25.00%
Sales 31.07M PEG - EPS past 5Y - 200D Avg Chg 63.00%
Dividend N/A Price/Book 11.75 EPS next 5Y - 52W High Chg -5.00%
Recommedations 3.00 Quick Ratio 10.70 Shares Outstanding 114.79M 52W Low Chg 298.00%
Insider Own 0.52% ROA -22.05% Shares Float 96.64M Beta 0.32
Inst Own 103.13% ROE -64.17% Shares Shorted/Prior 5.85M/9.30M Price 12.57
Gross Margin -160.03% Profit Margin - Avg. Volume 1,852,533 Target Price 32.50
Oper. Margin -74,557.90% Earnings Date May 13 Volume 787,234 Change -2.56%
About CymaBay Therapeutics Inc.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

CBAY Chatroom

User Image Ohzipit Posted - 1 week ago

With the manipulation we have seen since OW and especially today in a green market, I would say we are getting very close. Same occurred with $CCXI and more recently $CBAY leading into buyout. This smells of desperation. Shorts will be crushed!

User Image Auphiliate Posted - 1 month ago

$AUPH Okay, Iโ€™ll play along with GILD theory. Appears at least somewhat plausible. So here is the chart from a previous aquisition! $CBAY ๐Ÿ˜

User Image kinderspiel Posted - 3 months ago

with $GILD on the verge of an FDA decision for Seladelpar, the company has paid $JNJ $320 m to exit an 18-year-old licensing agreement the licensing deal was struck in 2006, with j&j agreeing to handle the patenting of seladelpar for $CBAY in february, gilead paid $4.3 billion to acquire the california biotech, which had positioned seladelpar for approval to treat PBC. an approval is expected to come by the FDA target date of Aug 14, with gilead standing 'ready to launch' $SPY

User Image PaidPumper420 Posted - 07/30/24

$EBS Look at how $CBAY behaved before they were bought. All good! :)

User Image Quokkary Posted - 4 months ago

$ICU There may be oodles of rich day traders / penny stock flippers; I just don't know any of them. I do know quite a few rich investors, though. It's a difference in mentality. And wisdom perhaps. The twitterpated hare scurries to and fro and is spent with nothing to show for it before the race is even over. The slow and steady tortoise puts one foot in front of the other and wins the race. Load up on this one, Thumper. Then go do other things. You'd be surprised how fast a year or two flies by, and then you wake up rich. Last one I did this with was $CBAY. An 18-month ten-bagger for me.

User Image Ohzipit Posted - 4 months ago

This team $VKTX @$11, $RNA @$5, $MIRM under $20 $CCXI and $CBAY both recent buyoutsโ€ฆI would say more often than most!

User Image dbr_island Posted - 06/26/24

Nobody had the balls or DD to call $CBAY going to DDโ€™s at these levelsโ€ฆ.. and called a BO๐Ÿ‘‡ BUT ME ๐Ÿ”ฎ Now I think NXL will be the next monster that hits DDโ€™s ๐Ÿ”ฎ ๐Ÿ”ฎ AND could also be a BO candidate ๐Ÿ”ฎ

User Image dbr_island Posted - 5 months ago

$VXRT Iโ€™m no psychic but I have been nailing these M&Aโ€™s more than the average person And I wouldnโ€™t be surprised if BIG PHARMA is paying a close eye on this company ๐Ÿ’Š Just like I predicted $CBAY would back when it was in the $4โ€™s๐Ÿ‘‡๐Ÿ”ฎ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ Itโ€™s all about risk/reward to me And at these levels Itโ€™s a NO BRAINER to me $ZAPP alerted in the .70โ€™s $MGOL what a strange news with a crude oil company ๐Ÿคท๐Ÿปโ€โ™‚๏ธ but watching

User Image JoNCherry Posted - 5 months ago

$ALLR still regretting sold $Cbay in 2sโ€ฆ. Otherwise have become millionaire

User Image Str8Shootn Posted - 5 months ago

@Stockerphysicshakws Yeah, they said the same about $CBAY. ๐Ÿ˜ฌ

User Image demetrin Posted - 6 months ago

@buythehornz127 @StillnessofBreath @Jeko44 @Investman13 @Fiftybucks Premium over some biotechnology bought out $PRVB $6.70 to $25 which was a 273% premium over the previous closing price Bought by SANOFI $CCXI to $24.11 to $52 which was a 116% premium over the previous closing price. Bought by AMGEN $GWPH $146.25 to $200 cash & $20 in Jazz stock Per share which was 50% premium over closing price. Bought by JAZZ $SGTX $3.93 to $22.47 which was 472% premium Bought by LILLY $CBAY $25.69 to $32.50 represents 27% premium over closing price Bought by GILEAD

User Image DaBullRunner Posted - 7 months ago

$ATHE as you can see I predicted $CBAY getting bought out from the $4โ€™s๐Ÿ‘‡๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ If the presentation comes out positive as it did last time This ticker could be an M&A target and at a major premium ๐Ÿฆ๐Ÿฆ๐Ÿฆ๐Ÿฆ $LXEH $RENT $CADL all paying me very well ๐Ÿ™

User Image DaBullRunner Posted - 7 months ago

$ATHE smart money not selling a single share under $5 This is a potential double digit ticker like I said $CBAY was before they got bought out

User Image dbr_island Posted - 7 months ago

Predicted that $CBAY was gonna get acquired๐Ÿ‘‡๐Ÿง™๐Ÿ”ฎ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ๐Ÿ’ฐ Now if $IGC keeps it up with their Phase 2-3 in ALZHEIMERS they could be the next to get acquired ๐Ÿ”ฎ๐Ÿง™๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ

User Image jacksparo Posted - 03/29/24

$ALT It is turn around momentum for us as a long term holder here. You know I got my history in reaching my price targets! In $DRCT $AQST $CBAY And a lot others I canโ€™t put them all in one postโœ…! But yes I am seeing a good time coming for ALT ๐Ÿ“ˆ๐Ÿ“ˆ! Wait for my incoming update about this via the email team ๐Ÿ’ฐ๐Ÿ’ต๐Ÿš€๐Ÿ’ฐ๐Ÿ’ต๐Ÿš€!

User Image Ohzipit Posted - 03/29/24

$ARDX RJF most recent comments dated 03/06. SS same analyst $CBAY @$5 $VKTX in the single digits, $RNA under single digits.

User Image Thinklikethecompany Posted - 03/28/24

$CBAY

User Image NEWBIGTECH Posted - 03/28/24

$SLS I hope all my friends are up to date on this amazing company. Do your own dd. I have been in $CBAY, $OPK $ATHE and others, this is great news on the cancer front. $SLS IS UNDERVALUED.

User Image Bjaccarini Posted - 03/28/24

$CBAY does anyone know when the second tender is to take place

User Image dbr_island Posted - 03/27/24

$YTEN red to green confirmed!!! ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ๐Ÿ“ˆ Iโ€™m telling you BIG AG is eyeing this company imo Read what I said about $CBAY ๐Ÿ‘‡๐Ÿง™๐Ÿ”ฎ๐Ÿ’ฐ๐Ÿ’ฐ

User Image CharlieBPupp Posted - 03/26/24

$HOOD is this going up because they locked up my $CBAY shares?

User Image Cal1f0rn1aBay Posted - 03/26/24

$KRTX $SPLK $AYX $CBAY $BKCC

User Image Yourmatefromdownunder Posted - 03/26/24

$CBAY Not happy! That was a BS buy out at far below the real value of the company, yes I made a boat load of cash but it should have been much much higher, as usual shareholders got ripped off!

User Image Norissa Posted - 03/26/24

$GILD $ASMB $CBAY

User Image StupediaTrades Posted - 03/24/24

$CBAY Each week we take a look at NASH Chart Watchlist and grade them A,B or C This Continues in beat mode.Congrats to all . Follow watchlist Grading by clicking the link in my profile.

User Image hockeypuckdude Posted - 8 months ago

$CBAY The release states that it should take a few business days

User Image hockeypuckdude Posted - 8 months ago

$CBAY

User Image immuz Posted - 8 months ago

$CBAY Anyone receive their cash yet?

User Image Practical Posted - 8 months ago

$CBAY I did not do anything to the tender. What happens to my holding now?

User Image immuz Posted - 8 months ago

$CBAY Thank you Behzad for another 800%+ return.

Analyst Ratings
HC Wainwright & Co. Neutral Feb 29, 24
Leerink Partners Market Perform Feb 20, 24
LifeSci Capital Market Perform Feb 14, 24
UBS Neutral Feb 14, 24
Piper Sandler Neutral Feb 14, 24
BTIG Neutral Feb 13, 24
HC Wainwright & Co. Neutral Feb 13, 24
Raymond James Market Perform Feb 13, 24
B. Riley Securities Neutral Feb 13, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
McWherter Charles President of R&D President of R&D Jan 19 Sell 23.67 18,403 435,599 15,000 01/22/24
McWherter Charles President of R&D President of R&D Jan 19 Option 5.26 18,403 96,800 18,125 01/22/24
Menold Daniel Vice President, Fina.. Vice President, Finance Jan 16 Sell 23.58 10,000 235,800 01/16/24
Menold Daniel Vice President, Fina.. Vice President, Finance Jan 16 Option 4.05 10,000 40,500 10,000 01/16/24
Quinlan Paul T General Counsel General Counsel Jan 16 Sell 23.58 5,000 117,900 01/16/24
Quinlan Paul T General Counsel General Counsel Jan 16 Option 2.94 5,000 14,700 5,000 01/16/24
Dorling Janet Director Director Jan 10 Sell 23.86 6,000 143,160 01/10/24
Dorling Janet Director Director Jan 10 Option 4.63 6,000 27,780 6,000 01/10/24
McWherter Charles President of R&D President of R&D Dec 18 Sell 21.48 11,332 243,411 15,000 12/18/23
McWherter Charles President of R&D President of R&D Dec 18 Option 5 11,332 56,660 21,504 12/18/23
Shah Sujal Chief Executive Offi.. Chief Executive Officer Dec 11 Sell 20.4 64,865 1,323,246 171,301 12/11/23
Shah Sujal Chief Executive Offi.. Chief Executive Officer Dec 11 Option 5 64,865 324,325 172,191 12/11/23
Dorling Janet Director Director Dec 11 Sell 20.07 6,000 120,420 12/11/23
Dorling Janet Director Director Dec 11 Option 4.63 6,000 27,780 6,000 12/11/23
McWherter Charles President of R&D President of R&D Nov 17 Sell 18.28 11,342 207,332 15,000 11/17/23
McWherter Charles President of R&D President of R&D Nov 17 Option 5 11,342 56,710 26,342 11/17/23
Menold Daniel Vice President, Fina.. Vice President, Finance Nov 15 Sell 17.38 11/17/23
Menold Daniel Vice President, Fina.. Vice President, Finance Nov 15 Option 3.45 17,500 60,375 17,500 11/17/23
Quinlan Paul T General Counsel General Counsel Nov 15 Sell 17.38 5,000 86,900 11/17/23
Quinlan Paul T General Counsel General Counsel Nov 15 Option 2.94 5,000 14,700 5,000 11/17/23
McWherter Charles President of R&D President of R&D Oct 18 Sell 14.07 21,743 305,924 15,000 10/18/23
McWherter Charles President of R&D President of R&D Oct 18 Option 5 21,743 108,715 36,743 10/18/23
Menold Daniel Vice President, Fina.. Vice President, Finance Oct 16 Sell 13.76 10/18/23
Menold Daniel Vice President, Fina.. Vice President, Finance Oct 16 Option 3.45 17,500 60,375 17,500 10/18/23
Quinlan Paul T General Counsel General Counsel Oct 16 Option 2.94 5,000 14,700 5,000 10/18/23
Quinlan Paul T General Counsel General Counsel Oct 16 Sell 13.76 5,000 68,800 10/18/23
Shah Sujal Chief Executive Offi.. Chief Executive Officer Oct 09 Sell 14.2 64,861 921,026 171,301 10/10/23
Shah Sujal Chief Executive Offi.. Chief Executive Officer Oct 09 Option 5 64,861 324,305 236,162 10/10/23
EMSTER KURT VON Director Director Sep 29 Sell 15.68 15,921 249,641 90,000 09/29/23
EMSTER KURT VON Director Director Sep 29 Option 5 15,921 79,605 105,921 09/29/23
McWherter Charles President of R&D President of R&D Sep 18 Sell 16.22 21,746 352,720 15,000 09/19/23
McWherter Charles President of R&D President of R&D Sep 18 Option 5 21,746 108,730 36,746 09/19/23
Menold Daniel Vice President, Fina.. Vice President, Finance Sep 15 Sell 16.87 09/19/23
Menold Daniel Vice President, Fina.. Vice President, Finance Sep 15 Option 1.77 16,545 29,285 15,000 09/19/23
Quinlan Paul T General Counsel General Counsel Sep 15 Sell 16.87 53,000 894,110 09/19/23
Quinlan Paul T General Counsel General Counsel Sep 15 Option 2.94 53,000 155,820 24,000 09/19/23
McWherter Charles President of R&D President of R&D Aug 18 Option 5 21,746 108,730 36,746 08/18/23
McWherter Charles President of R&D President of R&D Aug 18 Sell 11.47 21,746 249,427 15,000 08/18/23
Menold Daniel Vice President, Fina.. Vice President, Finance Aug 15 Sell 12.02 08/16/23
Menold Daniel Vice President, Fina.. Vice President, Finance Aug 15 Option 5.53 15,500 85,715 7,000 08/16/23
Quinlan Paul T General Counsel General Counsel Aug 15 Sell 11.91 5,000 59,550 08/16/23
Quinlan Paul T General Counsel General Counsel Aug 15 Option 2.94 5,000 14,700 5,000 08/16/23
Menold Daniel Vice President, Fina.. Vice President, Finance Aug 09 Sell 12.35 20,945 258,671 08/11/23
Menold Daniel Vice President, Fina.. Vice President, Finance Aug 09 Option 5 20,945 104,725 20,945 08/11/23
McWherter Charles President of R&D President of R&D Jul 18 Sell 11.43 21,749 248,591 15,000 07/19/23
McWherter Charles President of R&D President of R&D Jul 18 Option 5 21,749 108,745 36,749 07/19/23
Quinlan Paul T General Counsel General Counsel Jul 14 Sell 11.81 5,000 59,050 07/14/23
Quinlan Paul T General Counsel General Counsel Jul 14 Option 2.94 5,000 14,700 5,000 07/14/23
McWherter Charles President of R&D President of R&D Jun 20 Sell 8.16 21,749 177,472 15,000 06/21/23
McWherter Charles President of R&D President of R&D Jun 20 Option 5 21,749 108,745 36,749 06/21/23